Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.
A webcast of the presentation will be available under the 'Investors & News' section of the Finch website and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at Finch encourages investors to consult the "Investors & News" section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.
馬薩諸塞州薩默維爾,2022年5月17日(Global Newswire)--芬奇治療集團(以下簡稱芬奇或芬奇治療公司)(納斯達克代碼:FNCH),一家臨牀階段微生物組治療公司,利用其人類第一的發現®開發一種新型口服生物藥物的平臺今天宣佈,首席執行官Mark Smith博士將在2022年5月23-26日舉行的H.C.Wainwright全球投資會議上介紹公司概況。演示文稿將於2022年5月24日(星期二)美國東部時間上午7:00開始按需提供。
A webcast of the presentation will be available under the 'Investors & News' section of the Finch website and will be archived for approximately 30 days.
演示文稿的網絡直播將在Finch網站的‘Investors&News’部分進行,並將存檔約30天。
About Finch Therapeutics
芬奇治療公司簡介
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at Finch encourages investors to consult the "Investors & News" section of its website regularly.
芬奇治療公司是一家臨牀階段的微生物組治療公司,利用其人類第一的發現®開發一類新型口服生物藥物的平臺。憑藉開發完整和有針對性的微生物組療法的能力,Finch正在推進一系列豐富的候選藥物,旨在解決廣泛的未得到滿足的醫療需求。芬奇的主要候選藥物CP101正處於預防復發的晚期臨牀開發階段艱難梭菌並已獲得美國食品和藥物管理局的突破性治療和快速通道稱號。芬奇還在為患有自閉症譜系障礙和嚴重胃腸道症狀的兒童開發FIN-211。芬奇與武田建立了合作伙伴關係,專注於開發治療炎症性腸病的靶向微生物組療法。Finch經常在其網站Finch上發佈可能對投資者重要的信息,鼓勵投資者定期諮詢其網站的“Investors&News”部分。
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
人類第一的發現®是芬奇治療集團公司的註冊商標。
Investor Contact:
投資者聯繫方式:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
史蒂芬·賈斯珀
吉爾馬丁集團
(858) 525-2047
郵箱:stephen@gilmartinir.com
Media Contact:
媒體聯繫人:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
珍娜·厄本
貝瑞與公司公關
(212) 253-8881
郵箱:jUrban@berrypr.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧